THE FUTURE IN IMMUNOTHERAPY


Continue Reading

Cancer immunotherapies such as the monoclonal antibodies rituximab and trastuzumab are now familiar in the clinic. New and emerging treatments that harness the immune system to fight cancer offer options where previous choices were poor until recently, particularly for melanoma. These therapies are being tested in many types of cancer, and they offer hope for durable responses.


Kathy Boltz is a medical writer based in Phoenix, Arizona.


HOW TO TAKE THE POST-TEST: To obtain CE credit, please click here after reading the article to take the post-test on myCME.com.


REFERENCES

1. Raval RR, Sharabi AB, Walker AJ, et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014;2:14.

2. Buchbinder EI, McDermott DF. Interferon, interleukin-2, and other cytokines. Hematol Oncol Clin North Am. 2014;28(3):571-583.

3. Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1:12.

4. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.

5. Finn OJ. Cancer immunology. N Engl J Med. 2008;358(25):2704-2715.

6. About Kadcyla. Genentech. http://www.kadcyla.com/hcp/drug-information/her2-targeted-adc-structure. Accessed July 16, 2014.

7. Adcetris is a CD30 directed therapy. SeattleGenetics. http://adcetris.com/hcp/mechanism-of-action.php. Accessed July 16, 2014.

8. American Cancer Society. Cancer Immunotherapy. http://www.cancer.org/acs/
groups/cid/documents/webcontent/003013-pdf.pdf
. Accessed July 16, 2014.

9. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218-e228.

10. Leukine sargramostim. Sanofi-Aventis. http://www.leukine.com/patient-interstitial. Accessed July 16, 2014.

11. Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, et al. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol. 2014;27:89-97.

12. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.

13. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588(2):368-376.

14. Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. In: 2013 ASCO Annual Meeting; May 31-June 4, 2013; Chicago, IL; Abstract CRA9007.

15. Sznol M, Kluger H, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). In: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL. Abstract LBA9003.

16. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.

17. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.

18. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.

19. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.


HOW TO TAKE THE POST-TEST: To obtain CE credit, please click here after reading the article to take the post-test on myCME.com.